BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Issues Warning Letter to Warner Chilcott, PLC (WCRX) Suggesting Subpotent Birth Control Pills Problem


3/13/2012 8:22:58 AM

Yet another problem for Warner Chilcott. Last month, the drugmaker disclosed that the feds issued a subpoena for information on a wide array of sales and marketing activities (see here). Now, the FDA has issued a warning letter suggesting quality problems have existed for the past five years with the Ovcon birth control pill. The letter was prompted by an inspection last June of a Warner Chilcott plant in Puerto Rico. And the FDA notes the drugmaker did not thoroughly investigate identify the reason that certain lots of Ovcon failed stability testing going back to 2006. This can cause a problem with expiration dates. Meanwhile, Warner Chilcott continued to make Ovcon 50 tablets, even though these may have been subpotent.

Read at Pharmalot
Read at FDA

Pharmalot
FDA
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES